LumiThera reported positive findings in the LIGHTSITE III clinical trial evaluating the safety and efficacy of photobiomodulation with the Valeda light delivery system as a treatment for dry age-related macular degeneration.
One hundred patients were enrolled at 10 centers in the U.S. and randomly assigned to receive photobiomodulation (PBM) treatment or sham every 4 months for 2 years. The interim results were evaluated at 13 months and were found to be “very encouraging,” according to a company press release.
PBM uses a multi-wavelength approach to stimulate cellular function,